CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled / 25 target
Drug / intervention
Ebselen +1 moredrug
Likely dose
400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04483973
NCT04483973Phase 2CompletedUpdate Overdue (0.4/mo)Completion was 37mo ago
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

Sound Pharmaceuticals, Incorporated·interventional·Posted Jul 23, 2020·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating Ebselen and Placebo for Covid19 and 3 related conditions. Completed, enrolled 25 participants across 7 sites.

Signals

Enrollment appears stalled

Detailed Summary

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 23, 2020
Enrollment StartAug 27, 2021
Primary CompletionMay 5, 2023
Study CompletionJun 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.9 years ago

Arms & Interventions

Placeboplacebo_comparator

Oral administration of matching placebo BID for 14 days, with 30-day follow-up

Drug: Placebo
SPI-1005 400 mg BIDactive_comparator

Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up

Drug: Ebselen

Interventions

Ebselendrug

Glutathione peroxidase mimetic

Placebodrug

Matching placebo containing excipients